2022
DOI: 10.1016/j.celrep.2022.110993
|View full text |Cite
|
Sign up to set email alerts
|

KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
33
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 68 publications
(37 citation statements)
references
References 43 publications
4
33
0
Order By: Relevance
“…The inhibition ratio followed a dose-dependent manner in both of these cell lines and realgar induced apoptosis more efficiently in H23 cells. JNK and p38 have been shown to regulate a number of transcription factors, increasing the production of pro-apoptotic proteins while decreasing the expression of anti-apoptotic proteins ( 8 ). Through both transcriptional and post-translational mechanisms, ERK can be anti-apoptotic by upregulating anti-apoptotic proteins and downregulating pro-apoptotic proteins ( 51 ).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…The inhibition ratio followed a dose-dependent manner in both of these cell lines and realgar induced apoptosis more efficiently in H23 cells. JNK and p38 have been shown to regulate a number of transcription factors, increasing the production of pro-apoptotic proteins while decreasing the expression of anti-apoptotic proteins ( 8 ). Through both transcriptional and post-translational mechanisms, ERK can be anti-apoptotic by upregulating anti-apoptotic proteins and downregulating pro-apoptotic proteins ( 51 ).…”
Section: Discussionmentioning
confidence: 99%
“…In a single-group, phase 2 trial, treatment-related adverse events occurred in 88 of 126 patients (69.8%), including grade 3 events in 25 patients (19.8%) and a grade 4 event in 1 (0.8%) ( 7 ). In addition, the response rate of patients with NSCLC to AMG-510 is only 37% ( 8 ). It appears that the identification of effective and safe treatments for NSCLC caused by KRAS mutations remains an ongoing process.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Distinct signaling networks in lung and CRC might partly explain differences in clinical efficacy. Similar to BRAF V600E inhibition, targeting KRAS G12C and consecutive downregulation of MPAK pathway stimulates EGFR signaling via a negative feedback loop mechanism ( 39 41 ). This attenuates the efficacy of Sotorasib or Adagrasib and activates bypass mechanisms.…”
Section: Relevant Clinical Resistance Mechanismsmentioning
confidence: 99%
“…cancer with RAS wild-type tumors: The DEEPER trial (JACCRO CC-13). J Clin Oncol (2021) 39:3501-1. doi: 10.1200/jco.2021 39…”
mentioning
confidence: 99%